| 中文名 | 坦度替尼 |
|---|---|
| 英文名 | Tandutinib(CT 53518) |
| 中文别名 |
坦度替尼(标准品)
化合物:Tandutinib (MLN518) 4-[6-甲氧基-7-(3-哌啶-1-基丙氧基)喹唑啉-4-基]-N-(4-异丙基氧苯基)哌嗪-1-甲酰胺 坦度替尼,10 MM DMSO 溶液 Tandutinib (MLN518) 坦度替尼,S1043 化合物:Tandutinib (MLN518) Tandutinib (MLN518) :坦度替尼 Tandutinib (MLN518) 坦度替尼,S1043 N-(4-异丙氧基苯基)-4-(6-甲氧基-7-(3-(哌啶-1-基)丙氧基)喹唑啉-4-基)哌嗪-1-甲酰胺 坦度替尼(对照品) 坦度替尼 (MLN518) |
| 英文别名 |
Tandutinib(MLN518, CT53518)
MLN 518 4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}-N-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide Tandutinib(TINIBS) 1-Piperazinecboxamide, 4-(6-methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl) 4-[6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-cboxamide Abmole M1828-200mg Tandutinib 387-2 N-(4-Isopropoxyphenyl)-4-{6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl}-1-piperazinecarboxamide UNII:E1IO3ICJ9A Tandutinib CT53518 MLN518 CT-53518 MLN-518 Tandutinib 4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-Methylethoxy)phenyl] Tandutinib, 10 mM in DMSO 4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-cboxylic acid (4-isopropoxyphenyl)amide (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)cboxamide N-(4-Isopropoxyphenyl)-4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}piperazine-1-carboxamide Tandutinib for research N-(4-Isopropoxyphenyl)-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)piperazine-1 Tandutinib (MLN518, CT53518, NSC-726292) MLN518, Tandutinib N-(4-isopropoxyphenyl)-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)piperazine-1-cboxamide Tandutinib for NSC726292 4-(6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide CT53518; MLN518 (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)cboxamide Tandutinib(MLN518) Unii-E1io3icj9a 4-[6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-( 4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecboxamide Tandutinib //BP MLN518; CT53518; MLN 518; CT 53518; MLN-518; CT-53518 Tandutinib (CT53518, MLN518) |
| 描述 | Tandutinib(MLN518, CT53518)是FLT3拮抗剂,IC50为0.22 μM,还抑制PDGFR 和c-Kit。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 769.5±60.0 °C at 760 mmHg |
| 熔点 | 177-178°C |
| 分子式 | C31H42N6O4 |
| 分子量 | 562.703 |
| 闪点 | 419.2±32.9 °C |
| 精确质量 | 562.326782 |
| PSA | 92.29000 |
| LogP | 3.48 |
| 蒸汽压 | 0.0±2.6 mmHg at 25°C |
| 折射率 | 1.611 |
| 储存条件 | Refrigerator |
| 分子结构 | 1、 摩尔折射率:160.96 2、 摩尔体积(m3/mol):463.8 3、 等张比容(90.2K):1261.7 4、 表面张力(dyne/cm):54.7 5、 介电常数(F/m): 6、 偶极距(D): 7、 极化率(10 -24cm 3):63.81 |
| 计算化学 | 1.疏水参数计算参考值(XlogP):4.6 2.氢键供体数量:1 3.氢键受体数量:8 4.可旋转化学键数量:10 5.互变异构体数量:2 6.拓扑分子极性表面积92.3 7.重原子数量:41 8.表面电荷:0 9.复杂度:783 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
| 危害码 (欧洲) | T,N,Xi,F |
|---|---|
| 风险声明 (欧洲) | R25:Toxic if swallowed. R34:Causes burns. R50:Very Toxic to aquatic organisms. R40:Limited evidence of a carcinogenic effect. R36/37/38:Irritating to eyes, respiratory system and skin . |
| 安全声明 (欧洲) | S23-S37-S45-S61-S36-S26-S16 |
| 危险品运输编码 | UN 1751 6.1/PG 2 |
| WGK德国 | 2 |
| RTECS号 | AF8575000 |
| 包装等级 | II |
| 危险类别 | 6.1 |
| 海关编码 | 29154000 |
| 海关编码 | 29154000 |
|---|